Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track CRL with free AI briefings, catalyst countdowns, and dilution alerts.

CRL · CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$200.4M Cash on Hand
CF+ Cash Runway
Follow CRL by email Get an email when CRL reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about CRL, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Standard anticoagulation Pulmonary Embolism Phase 4 · NCT05493163 Completed
Thrombolytic Pulmonary Embolism Phase 4 · NCT05493163 Completed
Psilocybine Aging Phase 1 · NCT07719088 Not yet recruiting
Molnupiravir COVID-19 N/A · NCT07720596 Completed

Also used in these trials (approved or third-party drugs, not CRL's own candidates): Sevoflurane.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

CRL holds $200.4M in cash and short-term investments (as of Sep 26, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CRL files for a raise →

👥 Who Owns CRL

Insiders 1.1% Institutions (880 holders) 98.9% Public and other holders 0%
HolderTypeShares% of sharesAs of
FMR LLC Institution (13G, 5%+) 5,922,755 12.36% 2026-09-30
Vanguard Capital Management Institution (13G, 5%+) 3,634,376 7.58% 2026-03-31
T. Rowe Price Associates, Inc. Institution (13G, 5%+) 3,010,619 6.28% 2026-09-30
James C Foster
Director · +19,473 options
Insider 233,410 0.49% 2026-10-22
Birgit Girshick
Chief Executive Officer, Director · +8,722 options
Insider 79,288 0.17% 2026-08-19
Shannon M Parisotto
CEVP, Disc & Safety Assessment · +5,702 options
Insider 42,997 0.09% 2026-10-21
Joseph W LaPlume
EVP, Corp Strategy & Develop
Insider 31,041 0.06% 2026-08-10
Victoria L Creamer
EVP & Chief People Officer
Insider 30,051 0.06% 2026-08-06
Glenn Coleman
EVP & Chief Financial Officer
Insider 27,762 0.06% 2026-09-30
Martin Mackay
Director
Insider 17,137 0.04% 2026-05-08
Michael Gunnar Knell
SVP, Finance and CAO · +1,138 options
Insider 11,203 0.02% 2026-11-06
Mark Mintz
EVP, Chief Information Officer
Insider 9,546 0.02% 2026-05-29

Share count 47,917,467 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full CRL picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CRL and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.